What is Chardan Capital’s Estimate for COYA FY2025 Earnings?

Coya Therapeutics, Inc. (NASDAQ:COYA) – Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for Coya Therapeutics in a research report issued on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the company will post earnings per share of ($1.03) for the year, up from their prior forecast of ($1.26). Chardan Capital currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.14. The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.10 million.

Separately, D. Boral Capital reissued a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a report on Tuesday, March 18th.

Coya Therapeutics Stock Performance

NASDAQ COYA opened at $6.51 on Thursday. The stock has a market cap of $108.88 million, a PE ratio of -10.02 and a beta of 0.31. The firm has a 50-day moving average of $6.38 and a 200-day moving average of $6.50. Coya Therapeutics has a 52-week low of $4.75 and a 52-week high of $10.24.

Institutional Investors Weigh In On Coya Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of COYA. Tower Research Capital LLC TRC grew its stake in shares of Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after acquiring an additional 4,777 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Coya Therapeutics during the 4th quarter worth approximately $59,000. Jane Street Group LLC bought a new position in shares of Coya Therapeutics during the fourth quarter worth approximately $74,000. Northern Trust Corp raised its position in shares of Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after buying an additional 3,099 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at approximately $401,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.